Shanghai Pharmaceuticals Holding Co., Ltd.

Dell Products Inc.

Emc IP Holding Company LLC

Shanghai Fudan-zhangjiang Bio-pharmaceutical Co., Ltd.

Taizhou Fudan-zhangjiang Pharmaceutical Co., Ltd.

Shanghai Pharmaceuticals Holding Cd., Ltd.

Shanghai Bao Pharmaceuticals Co., Ltd.

Centre National De La Recherche Scientifique

Institut Curie

Urgo Recherche Innovation Et Developpement

Yanjun Liu

Guangxin Xia

Yu Mao

Di Li

Jing Jing Zhang

Qian Wang

Tao Zhang

Zhiqiang Hu

Hui Ge

Chen Shi

Xiong Zhai

Hongjian Zuo

Xuemei Liao

Lingjun Duan

Zhixiong Xiang

Guoyong Huo

Chi Chen

Zheng Wang

Zhen Zhu

Liang Zhao

Jia Xu

Maël Le Berre

Lin Lu

Matthieu Piel

Yanan Han

Ning Zhou

Tong Yang

Yijun Shen

Fang Wu

Jiansheng Han

Yong Chen

Ao Chen

Guangsheng Wu

Jinsong Wu

Wenbo Xiao

Provided are a mutant of an immunoglobulin degrading enzyme IdeE, a protein comprising the mutant, and a use of a composition and a kit in preparation of a drug for reducing the level of IgG in a subject. The mutant has amino acid substitution, N-terminal truncated and/or C-terminal truncated on one or more of positions 8, 10, 24, 59, 97, and 280 of the amino acid sequence shown in SEQ ID NO: 2, and the mutant has the function of the immunoglobulin degrading enzyme IdeE, and has higher activity and thermal stability than wild-type IdeE.

Use of mutant of immunoglobulin degrading enzyme IdeE

A method includes: acquiring a plurality of historical routes of movement of a plurality of historical users in a geographic area, wherein each historical route includes at least a portion of a plurality of locations; determining, based on the plurality of historical routes and a plurality of current positions of a plurality of users in the geographic area, a set of predicted locations among the plurality of locations that the plurality of users will visit in the future, respectively, wherein the plurality of users use a tour guiding service associated with the plurality of locations that is provided by a mobile network; selecting a set of popular locations from the set of predicted locations based on the number of users among the plurality of users who will visit each predicted location in the set of predicted locations; and scheduling tour guiding resources associated with the set of popular locations.

Method, device, and computer program product for scheduling tour guiding resources

Methods, apparatus, and processor-readable storage media for query processing based on a stochastic prediction model are provided herein. An example computer-implemented method includes maintaining information associated with a set of database operators corresponding to one or more historical query plans, wherein each of the historical query plans is associated with processing of a corresponding historical query in a database; building, based on the maintained information, a data structure comprising probabilities of each database operator in the set transitioning to each of one or more of the other database operators in the set; obtaining a new query to be processed in the database; applying a stochastic prediction algorithm to identify, from among the historical query plans, at least one candidate query plan for the new query based on the data structure; and executing the at least one candidate query plan to access data from the database for the new query.

Query processing based on stochastic prediction model

A nitrogenous heterocyclic compound, a preparation method, an intermediate, a composition, and an application. The present invention provides a nitrogenous heterocyclic compound as represented by formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, diastereoisomers thereof, tautomers thereof, solvates thereof, metabolites thereof, or prodrugs thereof. The compound has high inhibitory activity against ErbB2 tyrosine kinase, has good inhibitory activity against human breast cancer cells BT-474, human gastric cancer cells NCI-N87 and the like with high expression of ErbB2, and in addition has relatively weak inhibitory activity against EGFR kinase, that is, the compound is an EGFR/ErbB2 double target inhibitor that attenuates EGFR kinase inhibitory activity or a small-molecule inhibitor having selectivity for an ErbB2 target. 

Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application

The present invention discloses a substituted pyridine compound represented by formula I, and a pharmaceutically acceptable salt, stereoisomer and tautomer thereof. The compounds of the present invention are useful in the treatment of cancers. 

Substituted pyrimidines as cyclin-dependent kinase inhibitors

A salt of a quinazoline derivative (N-[4-(3-chlorine-4-fluoroanilino)]-7-(3-morpholinepropanol)-6-(2-fluoroacrylamide)-quinazoline, the structure thereof is as represented by formula I). Compared with a known quinazoline derivative, the salt of the quinazoline derivative has one or more improved properties and at least has better water solubility, wherein a citrate, a benzene sulfonate, and an ethanedisulphonate thereof further have better crystallinity and are not easy to absorb moisture. 

Salt of quinazoline derivative, preparation method therefor and application thereof

Disclosed are a nitrogenous heterocyclic compound, intermediates, a preparation method, a composition and use thereof. The nitrogenous heterocyclic compound in the present invention is as shown in formula I. The compound has a high inhibitory activity towards ErbB2 tyrosine kinase and a relatively good inhibitory activity towards human breast cancer BT-474 and human gastric cancer cell NCI-N87 which express ErbB2 at a high level, and at the same time has a relatively weak inhibitory activity towards EGFR kinase. Namely, the compound is a highly selective small-molecule inhibitor targeted at ErbB2, and hence it has a high degree of safety, and can effectively enlarge the safety window in the process of taking the drug. 

Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use

The present invention discloses a nitrogen-containing fused heterocyclic compound, as well as a preparation method, intermediate, composition and application thereof. The nitrogen-containing fused heterocyclic compound of the present invention as represented by formula (I), as well as the pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, metabolite or drug precursor thereof, exhibit a high selectivity and a high inhibitory activity with respect to CDK4 and CDK6 at a molecular level, an excellent inhibitory activity with respect to breast cancer cells at a cellular level, and significant inhibition of tumor cell proliferation associated with cyclin-dependent kinase activity at an animal level. The invention also exhibits a good stability with respect to human or mouse liver microsomes without significant inhibition of metabolic enzymes, good in vivo absorption in mice and rats, a high bioavailability and good druggability.

A soluble tumor necrosis factor receptor 2 (TNFRII) mutant has an amino acid substitution at position 92Glu compared with the wild TNFRII. The mutant improves the cytotoxicity capacity of neutralizing TNFalpha and lymphotoxin. The mutant and fusion protein comprising it are useful for the treatment of TNFalpha and lymphotoxin related diseases.

Soluble tumor necrosis factor receptor mutant

Growing community of inventors

Shanghai, China

Yanjun Liu